Fluidigm, OpGen Collaborate
News Jul 14, 2015
Under the terms of the five-year agreement, the firms will develop tests for the identification, screening, and surveillance of multi-drug resistant pathogens built on Fluidigm's Juno instrument for automating SNP genotyping assays and its Biomark real-time endpoint PCR. The firms will cooperate on quality and regulatory compliance and will have the option to extend the agreement for an additional five years.
"With this expanded relationship, OpGen anticipates developing customized solutions for our CLIA lab customers, strategic partners, and testing laboratories globally," OpGen President Kevin Krenitsky said in a statement, noting that the firm's Acuitas MDRO Gene Test and Resistome Test use Fluidigm's microfluidics.
Steve McPhail, Fluidigm's general manager for production genomics, said, that the partners will seek government funding to develop new products, including molecular information analytics, based on each other's technologies.
Gaithersburg, Maryland-based OpGen offers molecular testing and informatics to help healthcare organizations fight drug-resistant pathogens.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE